Clinical Trial

LYL273 for Patients With Relapsed or Refractory mCRC

Study acronym: CARABiNER
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-06-10
critical Phase changed: Phase 1 -> Phase 1/2 2026-06-04
critical Primary endpoint(s) modified 2026-06-04
notable Enrollment increased: 30 -> 155 participants 2026-06-04
Trial Details
NCT Number NCT05319314
Lead Sponsor Lyell Immunopharma, Inc.
Conditions Colorectal Cancer
Enrollment 155 participants
Start Date 2022-08-01
Primary Completion 2028-06 (estimated)
Study Completion 2032-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-09